Abstract:Background Desmoglein-2 (DSG2), a desmosomal adhesion molecule, is found to be closely related to tumorigenesis in recent years. However, the clinical value of DSG2 in lung adenocarcinoma remains unclear. Methods Real-time reverse transcription-quantitative polymerase chain reaction (qRT-PCR) was utilized to detect the expression of DSG2 in 40 paired lung adenocarcinoma tissues and corresponding non-cancerous tissues. Data from The Cancer Genome Atlas (TCGA) and Oncomine datasets were also downloaded and analyzed. The correlation between DSG2 and clinicopathological features was investigated. The expression of DSG2 protein by immunohistochemical was also detected from tissue microarray and the Human Protein Atlas database. Integrated meta-analysis combining the three sources (qRT-PCR data, TCGA data and Oncomine datasets) was performed to evaluate the clinical value of DSG2. Univariate and multivariate Cox regression analyses were used to explore the prognostic value of DSG2. Then, co-expressed genes were calculated by Pearson correlation analysis. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were used to investigate the underlying molecular mechanism. The expression level in lung adenocarcinoma and prognostic significance of the top ten co-expressed genes were searched from Gene Expression Profiling Interactive Analysis (GEPIA) online database. Results DSG2 was highly expressed in lung adenocarcinoma tissues based on qRT-PCR, TCGA and Oncomine datasets. The protein expression of DSG2 was also higher in lung adenocarcinoma. According to qRT-PCR and TCGA, high DSG2 expression was positively associated with tumor size (p = 0.027, p = 0.001), lymph node metastasis (p = 0.014, p < 0.001) and TNM stage (p = 0.023, p < 0.001). The combined standard mean difference values of DSG2 expression based on the three sources were 1.30 (95% confidence interval (CI): 1.08–1.52) using random effect model. The sensitivity and specificity were 0.73 (95% CI [0.69–0.76]) and 0.96 (95% CI [0.89–0.98]). The area under the curve based on summarized receiver operating characteristic (SROC) curve was 0.79 (95% CI [0.75–0.82]). Survival analysis revealed that high DSG2 expression was associated with a short overall survival (hazard ratio [HR] = 1.638; 95% CI [1.214–2.209], p = 0.001) and poor progression-free survival (HR = 1.475; 95% CI [1.102–1.974], p < 0.001). A total of 215 co-expressed genes were identified. According to GO and KEGG analyses, these co-expressed genes may be involved in “cell division”, “cytosol”, “ATP binding” and “cell cycle”. Based on GEPIA database, seven of the top ten co-expressed genes were highly expressed in lung adenocarcinoma (DSC2, SLC2A1, ARNTL2, ERO1L, ECT2, ANLN and LAMC2). High expression of these genes had shorter overall survival. Conclusions The expression of DSG2 is related to the tumor size, lymph node metastasis and TNM stage. Also, DSG2 predicts poor prognosis in lung adenocarcinoma.

Significance of Desmoglein‐2 on Cell Malignant Behaviors Via Mediating MAPK Signaling in Cervical Cancer

DSG2 and C-Myc Interact to Regulate the Expression of ADAM17 and Promote the Development of Cervical Cancer

Gene expression analyses identify a relationship between stanniocalcin 2 and the malignant behavior of colorectal cancer.

Up-regulated DSG2 promotes tumor growth and reduces immune infiltration in cervical cancer

Desmoglein-2 is Overexpressed in Non-Small Cell Lung Cancer Tissues and Its Knockdown Suppresses NSCLC Growth by Regulation of P27 and CDK2.

Elevated CISD2 Expression Predicts Poor Diagnosis and Promotes Invasion and Migration of Prostate Cancer Cells.

DSG2 Expression is Correlated with Poor Prognosis and Promotes Early-Stage Cervical Cancer

Upregulation of Desmoglein 2 and Its Clinical Value in Lung Adenocarcinoma: a Comprehensive Analysis by Multiple Bioinformatics Methods.

Characterization of Desmoglein 2 Expression in Ovarian Serous Tumors and Its Prognostic Significance in High-Grade Serous Carcinoma.

Serine/threonine‐protein kinase D2‐mediated phosphorylation of DSG2 threonine 730 promotes esophageal squamous cell carcinoma progression

Downregulation of desmoglein 2 promotes EMT progression in gallbladder cancer

Desmoglein-2 Modulates Tumor Progression and Osimertinib Drug Resistance Through the EGFR/Src/PAK1 Pathway in Lung Adenocarcinoma.

Desmoglein 2 and desmocollin 2 depletions promote malignancy through distinct mechanisms in triple-negative and luminal breast cancer

Down-regulated Desmocollin-2 Promotes Cell Aggressiveness Through Redistributing Adherens Junctions and Activating Beta-Catenin Signalling in Oesophageal Squamous Cell Carcinoma.

Up-regulation of Dsg2 Confered Stem Cells with Malignancy Through Wnt/β-Catenin Signaling Pathway.

Preliminary Study on the Role of the CSMD2 Gene in Bladder Cancer

Suprabasal Dsg2 expression in transgenic mouse skin confers a hyperproliferative and apoptosis-resistant phenotype to keratinocytes.

Downregulation of Diacylglycerol Kinase Zeta (DGKZ) Suppresses Tumorigenesis and Progression of Cervical Cancer by Facilitating Cell Apoptosis and Cell Cycle Arrest.

TOP2A Promotes Cell Migration, Invasion and Epithelial-Mesenchymal Transition in Cervical Cancer Via Activating the PI3K/AKT Signaling

Desmocollin-2 Inhibits Cell Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Via the ERK/c-MYC Signaling Pathway

MBD2 Facilitates Tumor Metastasis by Mitigating DDB2 Expression